ArticleJournal for immunotherapy of cancer2026

Targeting CD74 may mitigate immune-escape features and enhance BCMA CAR-T activity in preclinical models of relapsed/refractory multiple myeloma.

Xinzhuo Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.